JP2017531683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531683A5 JP2017531683A5 JP2017522213A JP2017522213A JP2017531683A5 JP 2017531683 A5 JP2017531683 A5 JP 2017531683A5 JP 2017522213 A JP2017522213 A JP 2017522213A JP 2017522213 A JP2017522213 A JP 2017522213A JP 2017531683 A5 JP2017531683 A5 JP 2017531683A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- therapeutically effective
- once
- formulation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 claims description 113
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 113
- 238000009472 formulation Methods 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 100
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 52
- 206010022437 insomnia Diseases 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 238000007922 dissolution test Methods 0.000 claims 4
- 238000004090 dissolution Methods 0.000 claims 3
- -1 (2,4-dimethylpyrimidin-5-yl) oxy Chemical group 0.000 claims 2
- 101000671811 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 37 Proteins 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 102100040111 Ubiquitin carboxyl-terminal hydrolase 37 Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 description 37
- 238000012360 testing method Methods 0.000 description 16
- 206010041349 Somnolence Diseases 0.000 description 8
- 208000032140 Sleepiness Diseases 0.000 description 7
- 230000037321 sleepiness Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000010365 information processing Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 230000003565 oculomotor Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067443P | 2014-10-23 | 2014-10-23 | |
| US62/067,443 | 2014-10-23 | ||
| PCT/JP2015/080304 WO2016063995A1 (en) | 2014-10-23 | 2015-10-21 | Compositions and methods for treating insomnia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531683A JP2017531683A (ja) | 2017-10-26 |
| JP2017531683A5 true JP2017531683A5 (enExample) | 2019-11-21 |
| JP6659681B2 JP6659681B2 (ja) | 2020-03-04 |
Family
ID=55761025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522213A Active JP6659681B2 (ja) | 2014-10-23 | 2015-10-21 | 不眠症を治療するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10188652B2 (enExample) |
| EP (1) | EP3209298B1 (enExample) |
| JP (1) | JP6659681B2 (enExample) |
| KR (1) | KR102444608B1 (enExample) |
| CN (1) | CN107810006B (enExample) |
| AU (1) | AU2015336463B2 (enExample) |
| BR (1) | BR112017007063A2 (enExample) |
| CA (1) | CA2964504C (enExample) |
| ES (1) | ES2843952T3 (enExample) |
| IL (1) | IL251759B (enExample) |
| MX (1) | MX376164B (enExample) |
| RU (1) | RU2703297C2 (enExample) |
| SG (2) | SG10202007759RA (enExample) |
| WO (1) | WO2016063995A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202007759RA (en) | 2014-10-23 | 2020-09-29 | Eisai R&D Man Co Ltd | Compositions and methods for treating insomnia |
| IL291791B2 (en) * | 2016-05-12 | 2025-09-01 | Eisai R&D Man Co Ltd | Methods for treating sleep timing disorders |
| CA3032233C (en) | 2016-08-10 | 2021-09-14 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising akt protein kinase inhibitors |
| CN115710250A (zh) | 2017-08-01 | 2023-02-24 | 博健制药有限责任公司 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
| CA3119728A1 (en) | 2018-11-21 | 2020-05-28 | Tremeau Pharmaceuticals, Inc. | Purified forms of rofecoxib, methods of manufacture and use |
| JP2022538170A (ja) * | 2019-06-26 | 2022-08-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 睡眠問題の治療のためのレンボレキサント |
| US20220305012A1 (en) * | 2019-06-26 | 2022-09-29 | Eisai R&D Management Co., Ltd. | Lemborexant for treating sleep issues |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| CN114502167A (zh) * | 2019-09-13 | 2022-05-13 | 卫材R&D管理有限公司 | 用于治疗失眠的药物组合物 |
| US20220339143A1 (en) * | 2019-09-13 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
| KR20220119065A (ko) | 2019-12-20 | 2022-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 불면증 치료를 위한 렘보렉산트의 용도 |
| TW202140014A (zh) | 2020-01-16 | 2021-11-01 | 日商衛材R&D企管股份有限公司 | 萊博雷生的原料藥及含有其的醫藥組成物 |
| EP4138822A1 (en) | 2020-04-19 | 2023-03-01 | Idorsia Pharmaceuticals Ltd | Medical use of daridorexant |
| CN111450076A (zh) * | 2020-05-25 | 2020-07-28 | 安徽省逸欣铭医药科技有限公司 | 一种Lemborexant软胶囊组合物及其制备方法 |
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06328057A (ja) | 1993-05-26 | 1994-11-29 | Sanyo Electric Co Ltd | 厨芥処理装置 |
| CA2220036A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human neuropeptide receptor |
| US6001963A (en) | 1996-12-17 | 1999-12-14 | Smithkline Beecham Corporation | Ligands of the neuropeptide receptor HFGAN72 |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| JP4094050B2 (ja) | 2004-03-01 | 2008-06-04 | アクテリオン ファーマシューティカルズ リミテッド | 置換１，２，３，４−テトラヒドロイソキノリン誘導体 |
| BRPI0515571A (pt) | 2004-09-23 | 2008-07-29 | Pfizer Prod Inc | agonistas de receptor de trombopoetina |
| JP2006328057A (ja) | 2005-04-25 | 2006-12-07 | Eisai R & D Management Co Ltd | 抗不安薬及びそのスクリーニング方法 |
| EP1998774A1 (en) | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinoline derivatives to enhance memory function |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| BRPI0716532A2 (pt) | 2006-09-11 | 2013-09-24 | Glaxo Group Ltd | compostos azabicÍclios como inidores de reabsorÇço de monoaminas |
| CL2007002809A1 (es) | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| TW200833328A (en) | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| AU2008303975B2 (en) | 2007-09-21 | 2013-05-16 | Sanofi | (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| EP2537282B1 (en) * | 2010-02-15 | 2015-09-16 | Koninklijke Philips N.V. | Mitigation of control channel interference |
| SI2626350T1 (sl) * | 2010-09-22 | 2015-09-30 | Eisai R&D Management Co., Ltd. | Spojina ciklopropana |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| SG10202007759RA (en) | 2014-10-23 | 2020-09-29 | Eisai R&D Man Co Ltd | Compositions and methods for treating insomnia |
-
2015
- 2015-10-21 SG SG10202007759RA patent/SG10202007759RA/en unknown
- 2015-10-21 ES ES15851934T patent/ES2843952T3/es active Active
- 2015-10-21 CN CN201580055472.XA patent/CN107810006B/zh active Active
- 2015-10-21 WO PCT/JP2015/080304 patent/WO2016063995A1/en not_active Ceased
- 2015-10-21 KR KR1020177009858A patent/KR102444608B1/ko active Active
- 2015-10-21 RU RU2017112308A patent/RU2703297C2/ru active
- 2015-10-21 EP EP15851934.8A patent/EP3209298B1/en active Active
- 2015-10-21 CA CA2964504A patent/CA2964504C/en active Active
- 2015-10-21 MX MX2017004950A patent/MX376164B/es active IP Right Grant
- 2015-10-21 BR BR112017007063-4A patent/BR112017007063A2/pt not_active Application Discontinuation
- 2015-10-21 AU AU2015336463A patent/AU2015336463B2/en active Active
- 2015-10-21 US US15/519,676 patent/US10188652B2/en active Active
- 2015-10-21 JP JP2017522213A patent/JP6659681B2/ja active Active
- 2015-10-21 SG SG11201703064WA patent/SG11201703064WA/en unknown
-
2017
- 2017-04-18 IL IL251759A patent/IL251759B/en active IP Right Grant
-
2019
- 2019-01-23 US US16/255,116 patent/US10702529B2/en active Active
-
2020
- 2020-03-16 US US16/819,341 patent/US11026944B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10959976B2 (en) | Methods and compositions for treating excessive sleepiness | |
| Findling et al. | A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. | |
| US10702529B2 (en) | Compositions and methods for treating insomnia | |
| JP2021130687A (ja) | ガボキサドールでの発達障害の処置方法 | |
| US11918551B2 (en) | Methods of treating seizure disorders and Prader-Willi syndrome | |
| JP2017081938A (ja) | パーキンソン病緩和のためのラサギリン | |
| US20220008398A1 (en) | Gaboxadol for reducing risk of suicide and rapid relief of depression | |
| JP2017510607A5 (enExample) | ||
| CN114786660A (zh) | 使用mtorc1调节剂的治疗方法 | |
| US20230404966A1 (en) | Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders | |
| US20230372335A1 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
| JP2024541978A (ja) | 進行期パーキンソン病のためのホスレボドパ／ホスカルビドパ皮下投与治療 | |
| US20250275953A1 (en) | Vodobatinib for reducing progression of parkinson's disease | |
| US20240197698A1 (en) | Treatment of acute anxiety with an alpha-7 nicotinic acetylcholine receptor modulator | |
| JP2026506886A (ja) | ドキシサイクリン単独またはレボドパとの組み合わせによる神経変性障害の治療 | |
| Muthalu et al. | Sedative and hemodynamic response of dexmedetomidine in critically ill South Indian population | |
| Yang et al. | Efficacy and safety of HSK16149 for postoperative pain in Chinese patients after orthopedic surgery: a phase 2 randomized clinical trial | |
| WO2025024428A1 (en) | Combination of taurursodiol (turso) and sodium phenylbutyrate for treating progressive supranuclear palsy | |
| Klimke et al. | Catatonia: current therapeutic recommendations | |
| JP6738797B2 (ja) | レット症候群治療薬 | |
| WO2025147467A1 (en) | 10mg to 35mg of gildeuretinol for use in the treatment of stargardt disease | |
| HK40097170A (zh) | 用加波沙朵治疗发育障碍的方法 | |
| Sullivan | Statins May Lower Risk of Dementia by 50% | |
| Demir et al. | Hypoxic-Ischemic Encephalopathy after Bee Sting and Treatment with Zolpidem: A Case Report | |
| Pepper | New drugs: To use or not to use |